Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma
NL-OMON53145Phase 1Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab, pomalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Recommended dose and regimen determination. Started Jan 2016; status: active, not recruiting.
02
Drugs
durvalumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53145.